SCHEMBL4063375

SCHEMBL4063375

O=[N+]([O-])c1ccc(Cc2nc3ncc(-c4ccco4)cc3[nH]2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 1/20 0.46
CHEK1 O14757 1/20 0.45
LIMK1 P53667 1/20 0.45
CDK5 Q00535 1/20 0.45
CLK4 Q9HAZ1 1/20 0.45
GRIN1 Q05586 1/20 0.43
GRIN2B Q13224 1/20 0.43
ADORA2A P29274 5/20 0.41
ADORA1 P30542 5/20 0.41
ADORA3 P0DMS8 1/20 0.39
ADORA2B P29275 1/20 0.39
MYC P01106 1/20 0.38
MAX P61244 1/20 0.38
MEN1 O00255 1/20 0.38
GAA P10253 1/20 0.38
PKM P14618 1/20 0.38
KMT2A Q03164 1/20 0.38
MAPT P10636 3/20 0.38
NPC1 O15118 1/20 0.38
MAPK1 P28482 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4055088 0.85 PRNP (0.42) ADORA2AADORA1ADORA3MEN1GAA
SCHEMBL4054333 0.85 GAA (0.43) RIPK1GAAPKMMAPTNPC1
SCHEMBL4059633 0.84 HPGD (0.38) ADORA2AADORA1ADORA3MEN1KMT2A
SCHEMBL4060932 0.84 MAPT (0.42) ADORA2AADORA1ADORA3MAPTNPC1
SCHEMBL4061234 0.84 NOS3 (0.45) ADORA2AADORA1ADORA3GAAPKM
SCHEMBL13608079 0.84 RIPK1 (0.46) RIPK1CHEK1LIMK1CDK5CLK4
SCHEMBL4051006 0.83 RIPK1 (0.46) RIPK1GRIN1GRIN2BMEN1GAA
SCHEMBL4057348 0.81 NOS3 (0.48) GRIN1GRIN2BADORA2AADORA1ADORA3
SCHEMBL4060685 0.81 KIT (0.42) ADORA2AADORA1ADORA3ADORA2B
SCHEMBL4051072 0.81 NOS3 (0.37) ADORA2AADORA1ADORA3GAAPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B RIPK1 1055/4885CHEK1 202/4885LIMK1 279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.